Akari Therapeutics (AKTX)
NASDAQ:AKTX
Total Valuation
Akari Therapeutics has a market cap or net worth of $4.39M. The enterprise value is -$982.25K.
Market Cap$4.39M
Enterprise Value-$982.25K
Share Statistics
Akari Therapeutics has 1,144,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,144,588
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Akari Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -44.99%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-44.99%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-2.16M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Akari Therapeutics is ―. Akari Therapeutics’s PEG ratio is 0.00881.
PE Ratio―
PS Ratio0.00
PB Ratio0.34
Price to Fair Value0.34
Price to FCF-0.92
Price to Operating Cash Flow-0.38
PEG Ratio0.00881
Income Statement
In the last 12 months, Akari Therapeutics had revenue of 0.00 and earned -17.30M in profits. Earnings per share was -24.00.
Revenue0.00
Gross Profit0.00
Operating Income-17.27M
Pretax Income-18.30M
Net Income-17.30M
EBITDA-17.27M
Earnings Per Share (EPS)-24.00
Cash Flow
In the last 12 months, operating cash flow was -8.40M and capital expenditures -4.00, giving a free cash flow of -8.40M billion.
Operating Cash Flow-8.40M
Free Cash Flow-8.40M
Free Cash Flow per Share-7.34
Dividends & Yields
Akari Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change-91.26%
50-Day Moving Average8.27
200-Day Moving Average24.23
Relative Strength Index (RSI)25.69
Average Volume (3m)1.63M
Important Dates
Akari Therapeutics upcoming earnings date is May 14, 2026, TBA (Confirmed).
Last Earnings DateApr 7, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
Akari Therapeutics as a current ratio of 0.44, with Debt / Equity ratio of 2.66%
Current Ratio0.44
Quick Ratio0.44
Debt to Market Cap0.08
Net Debt to EBITDA0.26
Interest Coverage Ratio-18.20
Taxes
In the past 12 months, Akari Therapeutics has paid -1.00M in taxes.
Income Tax-1.00M
Effective Tax Rate0.05
Enterprise Valuation
Akari Therapeutics EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.50.
EV to Sales0.00
EV to EBITDA-0.31
EV to Free Cash Flow-0.50
EV to Operating Cash Flow-0.50
Balance Sheet
Akari Therapeutics has $5.20M in cash and marketable securities with $754.00K in debt, giving a net cash position of $4.45M billion.
Cash & Marketable Securities$5.20M
Total Debt$754.00K
Net Cash$4.45M
Net Cash Per Share$3.89
Tangible Book Value Per Share-$16.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Akari Therapeutics is $27.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$27.00
Price Target Upside9542.86% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―